What Works Skin — Independent · Evidence-First · Ad-FreeIssue 014 · 20 April 2026 · Next: 04 Maywhatworksskin.com
What WorksSkin
Search/

Supplement · Pigmentation · IV glutathione

P. 13 · BRIEF

IV glutathione.

Clinic marketing. Evidence is thin.

The premium-priced sibling of the oral category, sold through aesthetic clinics as a 'whitening drip.' The published literature does not support the claims, the safety profile is more concerning than the marketing admits, and the FDA has issued warnings. Not a recommendation.

⁂

— § 02

What the literature shows.

Tone lightening (peer-reviewed)
Tiny trials, methodologically weak

The few positive trials are small, short, and rarely placebo-controlled. The aesthetic literature is closer to marketing than evidence.

25%
Melasma
—

No defensible RCT data. Oral tranexamic, topical hydroquinone, and azelaic vastly outperform on the endpoint and the cost ratio.

15%
'Antioxidant boost'
Acute biomarker shifts

Real, transient. Whether this matters clinically is unestablished. The same biomarker shifts can be achieved more cheaply.

30%
Adverse-event signal (Philippines FDA, 2011)
Regulatory warning

Reported renal, hepatic, and dermatological toxicity at higher doses. Take the warning seriously.

Caution
⁂

— § 03

Forms and bioavailability.

Clinic IV drip 600–1200 mg

Absorption · 100% bypassing gut

Once or twice weekly for 6–10 sessions. Premium pricing per session.

Push injection 600 mg

Absorption · 100%

Faster delivery; same efficacy questions. Same safety questions.

Compounded vitamin-C + glutathione drip

Absorption · 100%

Common combination at aesthetic clinics. Adds vitamin C complications to glutathione's own profile.

⁂

Bottom line

A category we cannot recommend. The marketing has outrun the evidence, and the safety profile makes the gap especially difficult to defend.

⁂

— § 04

Frequently asked.

Why is the FDA concerned?

The Philippines FDA issued a 2011 advisory citing reports of toxic epidermal necrolysis, Stevens-Johnson syndrome, renal and hepatic injury, and severe abdominal pain associated with IV glutathione marketed for skin lightening. The warning has been reiterated and other regulators have expressed similar caution.

Are clinic providers honest about the evidence?

Variably. The marketing typically presents the procedure as well-established. The literature presents the procedure as poorly-studied with non-trivial safety questions. The two pictures are difficult to reconcile.

What should I use instead?

Oral tranexamic acid (Tier A, RCT-supported), topical hydroquinone + tretinoin + niacinamide, and rigorous mineral SPF. The combination delivers measurably better melasma endpoints at a fraction of the cost and risk profile.

Is there any case where it makes sense?

Outside of clinical trials, no — and we say this rarely. The procedure neither reliably delivers the endpoints it markets nor sits within a safety profile that we can endorse.